Rituximab intolerance in patients with Waldenström macroglobulinaemia
Author:
Affiliation:
1. Bing Center for Waldenström Macroglobulinemia; Dana-Farber Cancer Institute; Boston MA USA
2. Harvard Medical School; Boston MA USA
Publisher
Wiley
Subject
Hematology
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.13794/fullpdf
Reference10 articles.
1. The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG);Buske;Leukemia,2009
2. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial;Hallek;Lancet,2010
3. Rituximab and subcutaneous 2-chloro-2’-deoxyadenosine combination treatment for patients with Waldenstrom macroglobulinemia: clinical and biologic results of a phase II multicenter study;Laszlo;Journal of Clinical Oncology,2010
4. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma;Marcus;Blood,2005
5. Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia;Owen;Seminars in Oncology,2003
Cited by 35 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Arrhythmia as the presenting symptom of a primary cardiac lymphoplasmacytic lymphoma;HeartRhythm Case Reports;2024-05
2. Waldenstrom Macroglobulinemia;Comprehensive Hematology and Stem Cell Research;2024
3. Nonviral cryoglobulinemic vasculitis: an updated review for clinical practice;Vessel Plus;2023-10-26
4. Monoclonal gammopathy of renal significance: Multidisciplinary approach to diagnosis and treatment;Critical Reviews in Oncology/Hematology;2023-03
5. Zanubrutinib in Treating Waldenström Macroglobulinemia, the Last Shall Be the First;Therapeutics and Clinical Risk Management;2022-06
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3